org_study_id,nct_id,brief_title,official_title,overall_status,start_date.text,start_date..attrs,completion_date.text,completion_date..attrs,completion_date_type,lead_sponsor/agency,overall_official.last_name,overall_official.role,overall_official.affiliation,phase,study_type,enrollment.text,enrollment..attrs,primary_condition,primary_outcome.measure,primary_outcome.time_frame,primary_outcome.description,primary_outcome.measure.1,primary_outcome.time_frame.1,primary_outcome.description.1,eligibility.gender,eligibility.minimum_age,eligibility.maximum_age,eligibility.healthy_volunteers,sponsors.lead_sponsor.agency,sponsors.lead_sponsor.agency_class,date_disclaimer
7625A-034,NCT03230838,MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034),"A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis",Not yet recruiting,"September 1, 2017",Anticipated,"September 6, 2020",Anticipated,Anticipated,Merck Sharp & Dohme Corp.,Medical Director,Study Director,Merck Sharp & Dohme Corp.,Phase 2,Interventional,120,Anticipated,Complicated Urinary Tract Infection; Pyelonephritis,Adverse Events (AEs),Up to Day 49,Number of participants with one or more AEs,Discontinuations,Up to Day 14,Number of participants who discontinued study drug due to an AE,All,N/A,17 Years,No,Merck Sharp & Dohme Corp.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017"
